ALMDT.PA Median Technologies down 17.15% pre-market 14 Feb 2026: watch support at €5.42

ALMDT.PA stock opened the pre-market session sharply lower after a one-day drop of -17.15%, trading at €5.46 on EURONEXT on 14 Feb 2026. Volume has surged to 1,927,008 shares, about 4.20x the average, signalling heavy selling pressure early in the session. The slide follows the company’s recent FDA 510(k) clearance headlines and mixed sector moves, leaving traders focused on near-term support at €5.42 and the 50-day average at €4.27 for clues about a rebound.

ALMDT.PA stock: Pre-market price action and key levels

Price action is the immediate story: ALMDT.PA stock is at €5.46, down €1.13 or -17.15% from the previous close of €6.59. The intraday range shows a low of €5.42 and a high of €6.87. Trade intensity is notable: volume is 1,927,008 vs average volume 459,151, a relative volume of 4.20. Short-term technical anchors include the 50-day average €4.27 and the 200-day average €2.97, which traders will watch as potential support areas.

ALMDT.PA stock: What likely drove the drop

The decline follows profit-taking after the Nasdaq Weekly Buzz highlighted Median’s recent FDA 510(k) clearance for eyonis LCS. Markets often react initially with increased volatility after regulatory milestones. In addition, biotech sector swings and broader healthcare rotation contributed. The release cited by Nasdaq shows mixed sentiment across the field; that article is a useful backdrop to today’s selling source. Local quote pages also showed intraday declines, confirming widespread selling interest source.

ALMDT.PA stock: Fundamentals and Meyka grade

Median Technologies (ALMDT.PA) operates in Healthcare, Medical – Devices, with market cap €200,150,452 and 36,657,592 shares outstanding. Trailing EPS is -1.16 and PE is -4.71. Current ratio is 0.35, cash per share €0.22, and price-to-sales is 8.59, reflecting growth expectations priced into a small free‑cash‑flow negative company. Meyka AI rates ALMDT.PA with a score out of 100: 68.89 (Grade B, Suggestion: HOLD). This grade factors S&P 500 and sector comparison, financial growth, key metrics and analyst consensus. These grades are informative only and not financial advice.

ALMDT.PA stock: Technicals, momentum and support

Technical indicators show mixed signals. RSI is 52.34, MACD ~ 0.32 with a neutral histogram, and ADX 42.50 indicating a strong short-term trend. Bollinger middle band is €3.80, upper €5.04, lower €2.56. Immediate support lies at the day low €5.42, then €4.27 (50-day MA) and €2.97 (200-day MA). Resistance appears at €6.87 intraday and the year high €7.27. High relative volume and an MFI of 74.24 suggest short-term distribution.

ALMDT.PA stock: Forecasts, price targets and scenario planning

Meyka AI’s forecast model projects a 12-month price of €2.91. Compared with the current price of €5.46, that implies an estimated downside of -46.63%. Short-term fair-value scenarios: a conservative base case target €3.00, reflecting cash and 200-day trend; a recovery case target €7.00 if commercial roll-out in the U.S. and EU accelerates; and a downside stress at €1.20 near the 52-week low if adoption stalls. Forecasts are model-based projections and not guarantees.

ALMDT.PA stock: Risks, catalysts and what to watch next

Key near-term catalysts include commercialization updates for eyonis LCS, CE marking progress expected Q2 2026, and clinical or distribution partnership announcements. Risks are funding and cash-flow pressure (operating cash flow per share -€0.72), low current ratio 0.35, and execution risk in enterprise sales. Watch quarterly volume trends, management guidance, and any updates to reimbursement pathways in the U.S. and Europe.

Final Thoughts

ALMDT.PA stock is trading as one of the pre-market top losers on 14 Feb 2026 after a heavy -17.15% move to €5.46 on EURONEXT, driven by profit-taking and sector volatility despite recent regulatory progress. Our technical read shows immediate support at €5.42, with meaningful structural support near the 50-day average €4.27 and the 200-day average €2.97. Meyka AI’s forecast model projects a 12-month price of €2.91, implying an estimated downside of -46.63% from today’s level; forecasts are model-based projections and not guarantees. For traders, high relative volume and an MFI of 74.24 suggest short-term distribution and elevated volatility. For longer-term investors, the path to upside depends on successful commercial roll-out, CE marking, and improvements in cash flow. We remain data-driven: watch upcoming commercial milestones, cash-burn updates, and any partnership deals that could reprice expectations. Meyka AI provides this analysis as an AI-powered market analysis platform, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.